Advances in Kinase Drug Discovery 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Macromolecules".
Deadline for manuscript submissions: closed (30 May 2022) | Viewed by 3203
Special Issue Editors
Interests: cellular signaling; lipid-activated protein kinases; identification of isoform-specific substrates of the AKT protein kinase; modulation of glycolytic vs. oxidative cellular phenotypes by signaling pathways in acute leukemia models; definition of the phosphorylome of primary blast cells from leukemia patients, and its modulation by the PI3K pathway; kinase-inhibitor therapy in hematological malignancies
Special Issues, Collections and Topics in MDPI journals
Interests: molecular mechanism in cancer; PI3K/Akt signaling; adaptive resistance to Akt inhibitors in prostate cancer; immunomodulatory properties of stem cells extracellular vesicle; neurodegenerative disorders
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are delighted to announce a call for submissions to a special issue of the International Journal of Molecular Sciences on the topic of Advances in Kinase Drug Discovery. More than fifty protein kinase inhibitors had been approved for clinical use to 11 December 2019, including seven in 2019, and many more were under clinical investigation (PKI-DB; https://www.icoa.fr/pkidb/index.html). Lipid, nucleotide and small molecule kinases represent equally interesting, if less often exploited therapeutic targets. Recent technological advances ranging from the application of biophysical techniques to ever larger and more complex systems to novel cellular target engagement assays, alongside a more nuanced understanding of resistance mechanisms have enabled exciting progress in this area of drug discovery.
We encourage submission of both original research articles and topical reviews on all aspects of drug discovery targeting the phosphotransferase enzyme family. All submitted articles will undergo peer review.
Prof. Dr. Sandra Marmiroli
Dr. Manuela Zavatti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- structure-guided drug discovery
- kinase inhibitor
- protein kinase
- lipid kinase
- nucleotide kinase
- sugar kinase
- fragment-based drug discovery
- allosteric inhibitor
- ATP-competitive inhibitor
- anticancer
- antibacterial
- antiviral
- anti-inflammatory
